Recombinant Anti-CD3 x Anti-IL2R Bispecific Antibody (scIgG) (SCIGG-093)

Recombinant Anti-CD3 x Anti-IL2R Bispecific Antibody (scIgG) is designed to be expressed as two chains, each chain has the same units with their parental IgG antibodies, anti-CD3 and anti-IL2R IgGs. The two chains form heterodimer via Fc KIH technology. This BsAb can retarget T cells to tumor cells. It is designed for the research of Hodgkin lymphoma; Non-Hodgkin's lymphoma (NHL); Acute lymphocytic leukemia (ALL) therapy.

Datasheet INQUIRY

Specifications

Targets

CD3 & IL2R

Type

Single chain IgGs

Species Reactivity

Human

Application

FuncS; Promising therapeutic agent

Related Disease

Hodgkin lymphoma; Non-Hodgkin's lymphoma (NHL); Acute lymphocytic leukemia (ALL)

Targets

Target 1

CD3

Gene ID

916

UniProt ID

P07766

Alternative Names

CD3; CD3E; CD3e molecule; Cluster of differentiation 3; CD3e molecule, epsilon (CD3-TCR complex); T3E; TCRE; IMD18; T-cell surface glycoprotein CD3 epsilon chain; CD3-epsilon; T-cell surface antigen T3/Leu-4 epsilon chain; CD3e antigen, epsilon polypeptide (TiT3 complex); T-cell antigen receptor complex, epsilon subunit of T3

Target 2

IL2R

Gene ID

3559

UniProt ID

P01589

Alternative Names

IL-2R; IL2R; Interleukin 2 receptor; p55; CD25; TCGFR; IDDM10; interleukin 2 receptor subunit alpha; IL2RA

Our products and services are for research use only, and not for use in diagnostic or therapeutic procedures.

Online Inquiry

Customer Reviews and Q&As

There are currently no customer reviews or questions for Recombinant Anti-CD3 x Anti-IL2R Bispecific Antibody (scIgG) (SCIGG-093). Click the button below to contact us or submit your feedback about this product.

Recombinant Anti-CD3 x Anti-IL2R Bispecific Antibody (scIgG) (CAT#: SCIGG-093)

Specifications

Targets

Customer Reviews and Q&As